Vancouver, British Columbia – October 23, 2025 – Pangea Natural Foods Inc. (CSE:PNGA) (OTC:PNGAF) (“ Pangea ” or the “ Company ”), is pleased to announce that its wholly owned subsidiary, Amino Innovations, has formed a strategic scientific collaboration partnership with two world-renowned pharmaceutical scientists, Dr. Neal Davies and Dr. Raimar Loebenberg, to accelerate the research, validation, and development of advanced non-injectable peptide delivery systems for consumer wellness applications.
Dr. Davies and Dr. Loebenberg, both senior professors in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, will provide formulation and validation expertise through a Research Services Agreement that leverages access to the University’s Drug Development and Innovation Centre (DDIC) and its state-of-the-art facilities, personnel, and pharmaceutical testing platforms.
Scope of Collaboration
Through this collaboration, Amino Innovations aims to establish a new benchmark for precision peptide delivery across oral, dermal, and topical formulations. The team will conduct in vitro, ex vivo, and in silico studies to quantify absorption, bioavailability, and stability of select peptides, including BPC-157, GHK-Cu, and KPV, using natural and safe permeation enhancers such as Tremella fuciformis (Snow Mushroom) and DMSO to improve efficacy and product performance.
Key areas of research include:
- Pharmacokinetic (PK) and pharmacodynamic (PD) modeling to optimize formulation parameters and delivery profiles
- Permeation and dissolution testing using skin and tissue-based membrane models
- Formulation refinement using natural excipients and botanical actives for enhanced bioavailability
- Stability and analytical testing to confirm product integrity and longevity
The data generated from this research will strengthen Amino Innovations’ growing intellectual property portfolio, enhance regulatory credibility, and accelerate new product development across the nutraceutical and cosmeceutical markets.
Dr. Neal Davies and Dr. Raimar Loebenberg stated, “We are thrilled to work with Amino Innovations, a company that is focused on evidence-based, non-injectable natural peptide innovation. Our expertise in biopharmaceutics, formulation science, and translational research will help bring forward validated peptide technologies with measurable impact in wellness and health science.”
Mr. Justin Kirkland, CSO and Co-Founder of Amino Innovations, commented, “This partnership gives us access to leading research expertise and infrastructure. By generating pharmacokinetic and permeability data on key peptide actives, we are creating a level of scientific transparency within the wellness industry.”
Mr. Pratap Sandhu, CEO of Pangea, added, “We are excited to support Amino Innovations as it continues to lead in science driven wellness innovation. This partnership reinforces our commitment to developing credible, research backed products that strengthen scientific integrity and drive long-term growth.”
About Pangea Natural Foods Inc.
Pangea Natural Foods Inc. is a North American manufacturer specializing in clean-label foods and innovative wellness products. Through its subsidiary Amino Innovations, the Company offers advanced, non-injectable peptide delivery systems that support recovery, cognitive function, and overall health.
On Behalf of the Board of Directors
“Pratap Sandhu”
Pratap Sandhu
CEO, Corporate Secretary and Director
+1 (604) 765-8069
media@pangeafood.com
Forward-Looking Information
This news release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. The forward–looking statements and information are based on certain key expectations and assumptions made by the management of the Company. As a result, there can be no assurance that the acquisition or related matters will be completed as proposed or at all. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward–looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the ability of the Company to complete its planned future activities and anticipated business plans. Other factors may also adversely affect the future results or performance of the Company, including general economic, market or business conditions, changes in the financial markets and changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history. Accordingly, readers should not place undue reliance on the forward–looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward– looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Featured Image @ Freepik